[NDUFAF2基因突变呈现为原发性肺高血压:一个病例报告]
Xiao-Dan Yan1, Yan-Yan Chen1, Li Tao1
1Department of Neonatology, Women and Children's Medical Center Affiliated to Guangzhou Medical University, Guangzhou 510600, China.
概括
NDUFAF2基因的突变与新生儿初级肺高血压和线粒体复合物I缺乏有关. 这一案例凸显了在严重的婴儿心脏病中基因分析的重要性.
科学领域:
- 遗传学 是一个遗传学.
- 新生儿医学 新生儿医学
- 心脏病学 心脏病学
背景情况:
- 新生儿持续性肺高血压 (PPHN) 是一种严重的疾病,通常需要密集治疗.
- 重症新生儿PPHN的遗传基础尚未完全理解,需要进一步研究.
- 线粒体复合体I缺乏症是一种已知的遗传性疾病,具有多样化的临床表现.
研究的目的:
- 在男性新生儿中调查新生儿初级肺高血压严重的遗传原因.
- 探索NDUFAF2基因突变与新生儿肺高血压之间的关联.
- 为了解重症新生儿心血管疾病的遗传因素作出贡献.
主要方法:
- 在新生儿和家人身上进行了全外体测序.
- 基因变异根据美国医学遗传学与基因组学学院的标准进行了分析.
- 尸检和肺组织电子显微镜进行了病理学检查.
主要成果:
- 在NDUFAF2基因中发现了复合异构基因突变 (c.192del和c.192_193del).
- 这些突变被证实是致病性的,并从父母双方遗传.
- 尸体解剖显示肺动脉扩张和心肌缩,没有膜毛细管发育不良.
结论:
- 这是第一个报告的病例,将NDUFAF2基因突变与新生儿初级肺高血压联系起来.
- NDUFAF2突变与线粒体复合体I缺陷有关,这表明一个潜在的机制.
- 遗传和病理学研究对于诊断和理解严重的新生儿疾病至关重要.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
300
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
300
Cystic Fibrosis: Pathogenesis
370
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
370
COPD: Pathogenesis and Clinical Features
544
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
544
Cardiomyopathy III: Hypertrophic Cardiomyopathy
67
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
67
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
263
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
263


